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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERBleeding, Stroke, and Antithrombotics in TAVI 2349
Josep Rodés-Cabau, Harold L. Dauerman, Mauricio G. Cohen, Roxana Mehran, Eric M. Small,
Susan S. Smyth, Marco A. Costa, Jessica L. Mega, Michelle L. O’Donoghue, E. Magnus Ohman,
Richard C. Becker
Patients undergoing transcatheter aortic valve implantation (TAVI) are at risk for both stroke
and bleeding complications. In this state-of-the-art paper, the authors review the current
deﬁnition, risks, mechanism, and timing of stroke and bleeding post-TAVI. Periprocedure
and post-procedure antithrombotic treatment and its potential inﬂuence on embolic and
bleeding complications are also discussed.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGYStent Thrombosis and Graft Occlusion in the SYNTAX Trial 2360
Vasim Farooq, Patrick W. Serruys, Yaojun Zhang, Michael Mack, Elisabeth Ståhle,
David R. Holmes, Ted Feldman, Marie-Claude Morice, Antonio Colombo, Christos V. Bourantas,
Ton de Vries, Marie-angèle Morel, Keith D. Dawkins, Arie Pieter Kappetein, Friedrich W. Mohr
This study evaluated the short- and long-term clinical impact of stent thrombosis (ST) and
graft occlusion (GO) in the ﬁnal 5-year outcome of the SYNTAX (SYNergy Between PCI
With TAXUS and Cardiac Surgery) trial. ST and GO were deﬁned with the SYNTAX
protocol deﬁnition, Academic Research Consortium (ARC) deﬁnition for ST, and the newly
devised ARC-like deﬁnition for GO. At 5 years, 871 of 903 (96.5%) patients in the
percutaneous coronary intervention cohort and 805 of 897 (89.7%) in the coronary artery
bypass graft cohort completed follow-up. As compared with other vessel locations, protocol
ST (n ¼ 47 subjects, 72 lesions) occurred more frequently in the left main (14 of 72, 19%)
and proximal coronary vasculature (37 of 72, 51%). Protocol-deﬁned GO (n ¼ 32, 41 lesions)
occurred more frequently with grafts anastomosed to the distal right coronary artery (17 of
41, 42%). Incidence of 5-year deﬁnite ST and deﬁnite GO did not signiﬁcantly differ (7% vs.
6%). Deﬁnite ST (n ¼ 48) was linked to 4 deaths at presentation and 17 deaths at 5 years.
Deﬁnite GO (n ¼ 32) was not linked to any mortality at presentation or at 5 years. The study
shows that ST and GO had a similar incidence at 5 years; however, the clinical impact of ST
appeared greater, with a negative impact on short- to longer-term mortality.(continued on page A-28)
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Gary Cheung, Neil Moat, Nikolaj Ihlemann, Matteo Ghione, Susanna Price, Alison Duncan,
Tine Streit Rosenberg, Sarah Barker, Carlo Di Mario, Magnus Settergren
The authors assessed the clinical and echocardiographic results of mitral clip implantation in
noncentral degenerative mitral regurgitation (dMR) compared with central dMR. From a
multicenter registry of patients treated with MitraClip (Abbott Vascular, Menlo Park,
California), 79 patients (age 79  8 years) with dMR were identiﬁed and analyzed.
Forty-nine patients (62%) had central dMR, with the remaining classiﬁed as noncentral
dMR. Patients with noncentral dMR had wider pre-procedural vena contracta (8.5 mm vs.
6.9 mm) and higher systolic pulmonary pressure (58 mm Hg vs. 47 mm Hg). Procedural
success, as well as post-procedural MR and New York Heart Association functional class, at 1
and 6 months did not differ between groups. There were also no differences in serious post-
procedural adverse events. The authors conclude that MitraClip treatment is safe and
effective in both central and noncentral dMR.
Editorial Comment: Jason H. Rogers, Reginald I. Low, p. 2378CARDIOMETABOLIC RISKPeriodontal Inﬂammation Reduction Through Statins 2382Sharath Subramanian, Hamed Emami, Esad Vucic, Parmanand Singh, Jayanthi Vijayakumar,
Kenneth M. Fifer, Achilles Alon, Sudha S. Shankar, Michael Farkouh, James H. F. Rudd, Zahi A. Fayad,
Thomas E. Van Dyke, Ahmed Tawakol
Periodontal disease (PD) is an independent risk factor for atherosclerosis. This study
evaluated whether high-dose statin treatment would result in a reduction in periodontal
inﬂammation as assessed by ﬂuorodeoxyglucose-positron emission tomography/computed
tomography (CT). A total of 83 adults with risk factors or with established atherosclerosis
were randomized to atorvastatin 80 mg versus 10 mg in a multicenter, double-blind trial to
evaluate the impact of atorvastatin on arterial inﬂammation. Periodontal inﬂammation was
also assessed. Additionally, periodontal bone loss (an index of PD severity) was evaluated
using contrast-enhanced CT images. At baseline, areas of severe PD had higher target-to-
background ratio (TBR) compared with areas without severe PD (mean TBR 3.83 vs. 3.18).
After 12 weeks, there was a signiﬁcant reduction in periodontal inﬂammation in patients
randomized to atorvastatin 80 mg versus 10 mg (DTBR mean 0.43). Changes in
periodontal inﬂammation correlated with changes in carotid inﬂammation. The authors
conclude that high-dose atorvastatin reduces periodontal inﬂammation. Given the
concomitant changes observed in periodontal and arterial inﬂammation, these data raise the
possibility that a portion of the beneﬁcial impact of statins on atherosclerosis is related to
reductions in extra-arterial inﬂammation (periodontitis).
Editorial Comment: Michael J. Blaha, Seth S. Martin, p. 2392(continued on page A-29)
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Maria Strom, Charu Ramanathan, Philippe Ritter, Michel Haïssaguerre, Pierre Jaïs, Theo Arts,
Tammo Delhaas, Frits W. Prinzen, Pierre Bordachar
In this study, the authors attempted to better understand the working mechanism of cardiac
resynchronization therapy (CRT). Hemodynamic response to left ventricular pacing (LVP)
and biventricular pacing (BiVP) was measured in 6 dogs and 24 patients with heart failure
and left bundle branch block (LBBB). Computer simulations of local myoﬁber mechanics
during LVP and BiVP in failing hearts with LBBB were also studied. Results revealed that
LVP and BiVP similarly increased the maximal rate of left ventricular (LV) pressure rise in
dogs and in patients, but only BiVP signiﬁcantly decreased electrical dyssynchrony. In
simulation, LVP and BiVP increased total ventricular myoﬁber work to the same extent.
However, the LVP-induced increase was entirely due to enhanced right ventricular (RV)
myoﬁber work, whereas the BiVP-induced increase was due to enhanced myoﬁber work of
both the LV and RV. The authors conclude that human and computational data support the
similarity of hemodynamic response to LVP and BiVP despite differences in electrical
dyssynchrony.
Editorial Comment: Claude Daubert, Albin Behaghel, Raphael P. Martins, p. 2404CARDIAC RESYNCHRONIZATIONSurvival Gain From Cardiac Resynchronization Therapy 2406
Judith A. Finegold, Claire E. Raphael, Wayne C. Levy, Zachary Whinnett, Darrel P. Francis
The landmark trials of biventricular pacing typically run for <1 battery life and may
underestimate lifespan beneﬁt over a longer duration. The authors performed a meta-analysis
of 5 landmark biventricular pacing trials (n = 6,561, average hazard ratio: 0.71) to calculate
lifespan gained within the duration of randomized controlled trial data up to 2 years, over a
5-year typical battery life, and over >1 battery life. Results revealed that lifespan gained across
all trials increases nonlinearly with time from 0.1 months at 1 year to 0.5 months at 2 years
and a projected 6.5 months at 5 years. Over a short window (2 years), lower-mortality
patients may gain less (1.36 months vs. 2.3 months), but by 15 years, their positions reverse
(16.0 months vs. 13.2 months). The authors conclude that life span gain from biventricular
pacing rises nonlinearly with time. Early on, high-risk patients show more gain, but later,
lower-risk patients show more gain.
Editorial Comment: J. Paul Mounsey, Jennifer D. Schwartz, p. 2414(continued on page A-30)
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Mikael K. Poulsen, Jordi S. Dahl, Jan Erik Henriksen, Thomas M. Hey,
Poul Flemming Høilund-Carlsen, Henning Beck-Nielsen, Jacob E. Møller
The authors evaluated the prognostic importance of left atrial dilation in patients with type 2
diabetes (T2DM) and no history of cardiovascular disease. A total of 305 T2DM patients
(age 58.6  11.3 years) without known cardiovascular disease were included. Patients
underwent cardiac evaluation and were followed (median 5.6 years) for occurrence of major
cardiac events and death. During follow-up, 60 patients (20%) experienced the composite
endpoint, of whom 28 (9%) died. Left atrial volume index (LAVi) 32 ml/m2 was found in
105 patients (34%). Patients with LAVi 32 ml/m2 had a signiﬁcantly higher cardiac event
and death rate. After adjusting for age and hypertension, only LAVi 32 ml/m2 was a
predictor of the composite endpoint (hazard ratio: 1.82). The study concluded that increased
LAVi was an independent and incremental predictor of cardiovascular morbidity and
mortality in T2DM patients with no history of cardiovascular disease.PRE-CLINICAL RESEARCH PRE-CLINICAL RESEARCHCarotid Body Denervation Improves Heart Failure Survival 2422
Rodrigo Del Rio, Noah J. Marcus, Harold D. Schultz
This study investigated whether selective ablation of carotid body (CB) chemoreceptors
improves cardiorespiratory control and survival during heart failure. Chronic heart failure
(CHF) was induced in rats by coronary ligation. Subsequently, selective carotid body
denervation (CBD) was performed to remove carotid chemoreﬂex drive in the CHF state.
Results revealed that CHF rats developed increased CB chemoreﬂex drive and chronic
central pre-sympathetic neuronal activation, increased indexes of sympathetic outﬂow,
increased breathing variability and apnea incidence, and desensitization of the baroreﬂex.
Selective CB ablation reduced the central pre-sympathetic neuronal activation by 40% and
normalized or improved all of the parameters studied. Early CB ablation also reduced cardiac
remodeling, deterioration of left ventricular ejection fraction, and cardiac arrhythmias, and
improved survival (85% vs. 45% survival of CHF rats without CBD). The authors conclude
that selective CBD may be of therapeutic valve in CHF.
Editorial Comment: Blair D. Johnson, Michael J. Joyner, p. 2431
